Nelson Craig M, Nazareth Blanca Arriola
Director of Medical Bioethics at the South Bay Medical Center in Harbor City, CA. E-mail:
Perm J. 2013 Summer;17(3):23-7. doi: 10.7812/TPP/12-124.
We established a fair and explicit nonbeneficial treatment and conflict resolution policy at our medical center. The policy was designed to help us acknowledge and respect both patients and clinicians involved in treatment planning and decision making.
To qualitatively describe how our hospitalwide nonbeneficial treatment and conflict resolution policy was used.
Retrospective evaluation of all bioethics consultations from November 6, 2009, when the policy was adopted, through August 6, 2012. Case-specific data were obtained when nonconsensus occurred involving withholding or withdrawing of nonbeneficial treatment.
Rates of resolution of conflicts and treatment plan consensus when nonbeneficial treatment was withheld or withdrawn.
We identified 146 (39.4%) cases where there was a treatment-level conflict between patients/surrogates and the treatment teams responsible for their care. In 54 (37.0%) of the cases, resolution occurred. In 92 (63.0%) of the cases, nonbeneficial treatment was eventually withheld or withdrawn. In 87 (94.6%) of the cases where treatment was withheld or withdrawn, the treatment teams and patients/surrogates reached consensus by the conclusion of the bioethics consultation process using the fair and explicit nonbeneficial treatment and conflict resolution policy.
A fair and explicit nonbeneficial treatment and conflict resolution policy can result in a high level of consensus between patients/surrogates and the treatment teams responsible for their care when treatment is withheld or withdrawn.
我们在医疗中心制定了一项公平且明确的无益处治疗及冲突解决政策。该政策旨在帮助我们承认并尊重参与治疗规划和决策的患者及临床医生。
定性描述我们全院范围的无益处治疗及冲突解决政策是如何被运用的。
对2009年11月6日(该政策采用之日)至2012年8月6日期间所有生物伦理咨询进行回顾性评估。当在涉及放弃或撤销无益处治疗出现意见不一致时获取具体病例数据。
当放弃或撤销无益处治疗时冲突的解决率及治疗计划的共识率。
我们确定了146例(39.4%)患者/代理人与负责其治疗的医疗团队之间存在治疗层面冲突的病例。其中54例(37.0%)冲突得到解决。92例(63.0%)最终放弃或撤销了无益处治疗。在87例(94.6%)放弃或撤销治疗的病例中,通过运用公平且明确的无益处治疗及冲突解决政策,医疗团队与患者/代理人在生物伦理咨询过程结束时达成了共识。
一项公平且明确的无益处治疗及冲突解决政策能够在放弃或撤销治疗时,使患者/代理人与负责其治疗的医疗团队之间达成高度共识。